Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Hospital-based Retrospective Study of Cryptococcal Meningitis in a Large Cohort from India.

Naik KR, Saroja AO, Doshi DK.

Ann Indian Acad Neurol. 2017 Jul-Sep;20(3):225-228. doi: 10.4103/aian.AIAN_39_17.

2.

Disseminated Cryptococcosis with Adrenal Insufficiency and Meningitis in an Immunocompetent Individual.

Ito M, Hinata T, Tamura K, Koga A, Ito T, Fujii H, Hirata F, Sakuta H.

Intern Med. 2017;56(10):1259-1264. doi: 10.2169/internalmedicine.56.7356. Epub 2017 May 15.

3.

Factors associated with early mycological clearance in HIV-associated cryptococcal meningitis.

Concha-Velasco F, González-Lagos E, Seas C, Bustamante B.

PLoS One. 2017 Mar 29;12(3):e0174459. doi: 10.1371/journal.pone.0174459. eCollection 2017.

4.

Dectin-3 Is Not Required for Protection against Cryptococcus neoformans Infection.

Campuzano A, Castro-Lopez N, Wozniak KL, Leopold Wager CM, Wormley FL Jr.

PLoS One. 2017 Jan 20;12(1):e0169347. doi: 10.1371/journal.pone.0169347. eCollection 2017.

5.

Integrated therapy for HIV and cryptococcosis.

Srichatrapimuk S, Sungkanuparph S.

AIDS Res Ther. 2016 Nov 29;13(1):42. Review.

6.

Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the Evidence.

Montezuma-Rusca JM, Powers JH, Follmann D, Wang J, Sullivan B, Williamson PR.

PLoS One. 2016 Aug 4;11(8):e0159727. doi: 10.1371/journal.pone.0159727. eCollection 2016. Review.

7.

Antifungal Activity of Plasmacytoid Dendritic Cells against Cryptococcus neoformans In Vitro Requires Expression of Dectin-3 (CLEC4D) and Reactive Oxygen Species.

Hole CR, Leopold Wager CM, Mendiola AS, Wozniak KL, Campuzano A, Lin X, Wormley FL Jr.

Infect Immun. 2016 Aug 19;84(9):2493-504. doi: 10.1128/IAI.00103-16. Print 2016 Sep.

8.

Combinatorial strategies for combating invasive fungal infections.

Spitzer M, Robbins N, Wright GD.

Virulence. 2017 Feb 17;8(2):169-185. doi: 10.1080/21505594.2016.1196300. Epub 2016 Jun 7. Review.

9.

HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings.

Tenforde MW, Wake R, Leeme T, Jarvis JN.

Curr Clin Microbiol Rep. 2016;3:92-102. Epub 2016 Mar 17. Review.

10.

Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis.

Tugume L, Morawski BM, Abassi M, Bahr NC, Kiggundu R, Nabeta HW, Hullsiek KH, Taseera K, Musubire AK, Schutz C, Muzoora C, Williams DA, Rolfes MA, Meintjes G, Rhein J, Meya DB, Boulware DR.

HIV Med. 2017 Jan;18(1):13-20. doi: 10.1111/hiv.12387. Epub 2016 Apr 28.

11.

Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis.

Merry M, Boulware DR.

Clin Infect Dis. 2016 Jun 15;62(12):1564-8. doi: 10.1093/cid/ciw151. Epub 2016 Mar 23.

12.

Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.

Rhein J, Morawski BM, Hullsiek KH, Nabeta HW, Kiggundu R, Tugume L, Musubire A, Akampurira A, Smith KD, Alhadab A, Williams DA, Abassi M, Bahr NC, Velamakanni SS, Fisher J, Nielsen K, Meya DB, Boulware DR; ASTRO-CM Study Team.

Lancet Infect Dis. 2016 Jul;16(7):809-818. doi: 10.1016/S1473-3099(16)00074-8. Epub 2016 Mar 10.

13.

Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome.

Leopold Wager CM, Hole CR, Wozniak KL, Wormley FL Jr.

Front Microbiol. 2016 Feb 9;7:105. doi: 10.3389/fmicb.2016.00105. eCollection 2016. Review.

14.

Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.

Beardsley J, Wolbers M, Kibengo FM, Ggayi AB, Kamali A, Cuc NT, Binh TQ, Chau NV, Farrar J, Merson L, Phuong L, Thwaites G, Van Kinh N, Thuy PT, Chierakul W, Siriboon S, Thiansukhon E, Onsanit S, Supphamongkholchaikul W, Chan AK, Heyderman R, Mwinjiwa E, van Oosterhout JJ, Imran D, Basri H, Mayxay M, Dance D, Phimmasone P, Rattanavong S, Lalloo DG, Day JN; CryptoDex Investigators.

N Engl J Med. 2016 Feb 11;374(6):542-54. doi: 10.1056/NEJMoa1509024.

15.

Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis.

Rolfes MA, Rhein J, Schutz C, Taseera K, Nabeta HW, Huppler Hullsiek K, Akampuira A, Rajasingham R, Musubire A, Williams DA, Thienemann F, Bohjanen PR, Muzoora C, Meintjes G, Meya DB, Boulware DR.

Open Forum Infect Dis. 2015 Dec 28;2(4):ofv157. doi: 10.1093/ofid/ofv157. eCollection 2015 Dec.

16.

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.

Bicanic T, Bottomley C, Loyse A, Brouwer AE, Muzoora C, Taseera K, Jackson A, Phulusa J, Hosseinipour MC, van der Horst C, Limmathurotsakul D, White NJ, Wilson D, Wood R, Meintjes G, Harrison TS, Jarvis JN.

Antimicrob Agents Chemother. 2015 Dec;59(12):7224-31. doi: 10.1128/AAC.01698-15. Epub 2015 Sep 8.

18.

Analysis of cerebrospinal fluid protein concentrations of patients with cryptococcal meningitis treated with antifungal agents.

Huang L, Ye H, Qu J, Liu Y, Zhong C, Tang G, Liu Y, Huang Y, Lv X.

BMC Infect Dis. 2015 Aug 13;15:333. doi: 10.1186/s12879-015-1063-0.

19.

Epidemiological characterization and prognostic factors in patients with confirmed cerebral cryptococcosis in central Taiwan.

Chen CH, Sy HN, Lin LJ, Yen HC, Wang SH, Chen WL, Chen YM, Chang YJ.

J Venom Anim Toxins Incl Trop Dis. 2015 May 12;21:12. doi: 10.1186/s40409-015-0012-0. eCollection 2015.

20.

Combination Therapy for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Whom, When, and Where?

Siedner MJ, Campbell JI, Kanters S, Bennett JE, Thorlund K, Tsai AC, Mills EJ.

Open Forum Infect Dis. 2015 May 13;2(2):ofv071. doi: 10.1093/ofid/ofv071. eCollection 2015 Apr. No abstract available.

Supplemental Content

Support Center